カテゴリー： QYResearch, 世界

世界の二次性副甲状腺機能亢進薬市場 2019年

【英語タイトル】Global Secondary Hyperparathyroidism Drug Market Professional Survey Report 2019

QYResearchが出版した調査資料（DATA909X14807）・商品コード：DATA909X14807
・発行会社（調査会社）：QYResearch
・発行日：2019年11月20日（※2024年版があります。お問い合わせください）
・ページ数：105
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後3営業日）
・調査対象地域：グローバル
・産業分野：医薬品・ヘルスケア
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,500 ⇒換算￥518,000見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD5,250 ⇒換算￥777,000見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD7,000 ⇒換算￥1,036,000見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・郵送（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
※本調査レポートは、二次性副甲状腺機能亢進薬の世界市場概要、製造コスト分析、開発・製造工場分析、主要メーカー分析、地域別分析情報、市場規模予測データ、マーケティングチャネル、流通業者リスト、顧客リストなどが含まれています。種類別には、エボカルセト、LNP-1892、AJT-240、シナカルセト塩酸塩、CTA-091、その他に、用途別には、病院、診療所、その他にセグメント区分し、二次性副甲状腺機能亢進薬の世界市場を分析しました。


・エグゼクティブ・サマリー
・二次性副甲状腺機能亢進薬の世界市場概要
・二次性副甲状腺機能亢進薬の製造コスト構成分析
・二次性副甲状腺機能亢進薬の開発・製造工場分析
・主要メーカーの主な指標（生産能力、売上、価格分析）
・二次性副甲状腺機能亢進薬の地域別分析（生産、売上、主要メーカー、輸出・輸入）
（北米、ヨーロッパ、中国、日本国内、東南アジア、インド）
・二次性副甲状腺機能亢進薬のセグメント分析（種類別）
（エボカルセト、LNP-1892、AJT-240、シナカルセト塩酸塩、CTA-091、その他）
・二次性副甲状腺機能亢進薬のセグメント分析（用途別）
（病院、診療所、その他）
・二次性副甲状腺機能亢進薬の主要メーカー別分析（生産拠点、製品概要、生産・売上実績）
（Deltanoid Pharmaceuticals Inc、EA Pharma Co Ltd、Lupin Ltd、Mitsubishi Tanabe Pharma Corp、OPKO Health Inc、Shire Plc、）
・二次性副甲状腺機能亢進薬の市場規模予測（2019年～2025年）
（北米、ヨーロッパ、中国、日本国内、東南アジア、インド）
・マーケティングチャネル・流通業者・顧客
・市場ダイナミクス（市場動向、機会、成長要因、課題、影響因子）
...
【レポートの概要】

The global Secondary Hyperparathyroidism Drug market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025.
This report focuses on Secondary Hyperparathyroidism Drug volume and value at global level, regional level and company level. From a global perspective, this report represents overall Secondary Hyperparathyroidism Drug market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Secondary Hyperparathyroidism Drug in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Secondary Hyperparathyroidism Drug manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Deltanoid Pharmaceuticals Inc
EA Pharma Co Ltd
Lupin Ltd
Mitsubishi Tanabe Pharma Corp
OPKO Health Inc
Shire Plc
…

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Evocalcet
LNP-1892
AJT-240
Cinacalcet Hydrochloride
CTA-091
Others

Segment by Application
Hospital
Clinic
Others

【レポートの目次】

Table of Contents

Executive Summary
1 Industry Overview of Secondary Hyperparathyroidism Drug
1.1 Definition of Secondary Hyperparathyroidism Drug
1.2 Secondary Hyperparathyroidism Drug Segment by Type
1.2.1 Global Secondary Hyperparathyroidism Drug Production Growth Rate Comparison by Types (2014-2025)
1.2.2 Evocalcet
1.2.3 LNP-1892
1.2.4 AJT-240
1.2.5 Cinacalcet Hydrochloride
1.2.6 CTA-091
1.2.7 Others
1.3 Secondary Hyperparathyroidism Drug Segment by Applications
1.3.1 Global Secondary Hyperparathyroidism Drug Consumption Comparison by Applications (2014-2025)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Secondary Hyperparathyroidism Drug Overall Market
1.4.1 Global Secondary Hyperparathyroidism Drug Revenue (2014-2025)
1.4.2 Global Secondary Hyperparathyroidism Drug Production (2014-2025)
1.4.3 North America Secondary Hyperparathyroidism Drug Status and Prospect (2014-2025)
1.4.4 Europe Secondary Hyperparathyroidism Drug Status and Prospect (2014-2025)
1.4.5 China Secondary Hyperparathyroidism Drug Status and Prospect (2014-2025)
1.4.6 Japan Secondary Hyperparathyroidism Drug Status and Prospect (2014-2025)
1.4.7 Southeast Asia Secondary Hyperparathyroidism Drug Status and Prospect (2014-2025)
1.4.8 India Secondary Hyperparathyroidism Drug Status and Prospect (2014-2025)

2 Manufacturing Cost Structure Analysis
2.1 Raw Material and Suppliers
2.2 Manufacturing Cost Structure Analysis of Secondary Hyperparathyroidism Drug
2.3 Manufacturing Process Analysis of Secondary Hyperparathyroidism Drug
2.4 Industry Chain Structure of Secondary Hyperparathyroidism Drug

3 Development and Manufacturing Plants Analysis of Secondary Hyperparathyroidism Drug
3.1 Capacity and Commercial Production Date
3.2 Global Secondary Hyperparathyroidism Drug Manufacturing Plants Distribution
3.3 Major Manufacturers Technology Source and Market Position of Secondary Hyperparathyroidism Drug
3.4 Recent Development and Expansion Plans

4 Key Figures of Major Manufacturers
4.1 Secondary Hyperparathyroidism Drug Production and Capacity Analysis
4.2 Secondary Hyperparathyroidism Drug Revenue Analysis
4.3 Secondary Hyperparathyroidism Drug Price Analysis
4.4 Market Concentration Degree

5 Secondary Hyperparathyroidism Drug Regional Market Analysis
5.1 Secondary Hyperparathyroidism Drug Production by Regions
5.1.1 Global Secondary Hyperparathyroidism Drug Production by Regions
5.1.2 Global Secondary Hyperparathyroidism Drug Revenue by Regions
5.2 Secondary Hyperparathyroidism Drug Consumption by Regions
5.3 North America Secondary Hyperparathyroidism Drug Market Analysis
5.3.1 North America Secondary Hyperparathyroidism Drug Production
5.3.2 North America Secondary Hyperparathyroidism Drug Revenue
5.3.3 Key Manufacturers in North America
5.3.4 North America Secondary Hyperparathyroidism Drug Import and Export
5.4 Europe Secondary Hyperparathyroidism Drug Market Analysis
5.4.1 Europe Secondary Hyperparathyroidism Drug Production
5.4.2 Europe Secondary Hyperparathyroidism Drug Revenue
5.4.3 Key Manufacturers in Europe
5.4.4 Europe Secondary Hyperparathyroidism Drug Import and Export
5.5 China Secondary Hyperparathyroidism Drug Market Analysis
5.5.1 China Secondary Hyperparathyroidism Drug Production
5.5.2 China Secondary Hyperparathyroidism Drug Revenue
5.5.3 Key Manufacturers in China
5.5.4 China Secondary Hyperparathyroidism Drug Import and Export
5.6 Japan Secondary Hyperparathyroidism Drug Market Analysis
5.6.1 Japan Secondary Hyperparathyroidism Drug Production
5.6.2 Japan Secondary Hyperparathyroidism Drug Revenue
5.6.3 Key Manufacturers in Japan
5.6.4 Japan Secondary Hyperparathyroidism Drug Import and Export
5.7 Southeast Asia Secondary Hyperparathyroidism Drug Market Analysis
5.7.1 Southeast Asia Secondary Hyperparathyroidism Drug Production
5.7.2 Southeast Asia Secondary Hyperparathyroidism Drug Revenue
5.7.3 Key Manufacturers in Southeast Asia
5.7.4 Southeast Asia Secondary Hyperparathyroidism Drug Import and Export
5.8 India Secondary Hyperparathyroidism Drug Market Analysis
5.8.1 India Secondary Hyperparathyroidism Drug Production
5.8.2 India Secondary Hyperparathyroidism Drug Revenue
5.8.3 Key Manufacturers in India
5.8.4 India Secondary Hyperparathyroidism Drug Import and Export

6 Secondary Hyperparathyroidism Drug Segment Market Analysis (by Type)
6.1 Global Secondary Hyperparathyroidism Drug Production by Type
6.2 Global Secondary Hyperparathyroidism Drug Revenue by Type
6.3 Secondary Hyperparathyroidism Drug Price by Type

7 Secondary Hyperparathyroidism Drug Segment Market Analysis (by Application)
7.1 Global Secondary Hyperparathyroidism Drug Consumption by Application
7.2 Global Secondary Hyperparathyroidism Drug Consumption Market Share by Application (2014-2019)

8 Secondary Hyperparathyroidism Drug Major Manufacturers Analysis
8.1 Deltanoid Pharmaceuticals Inc
8.1.1 Deltanoid Pharmaceuticals Inc Secondary Hyperparathyroidism Drug Production Sites and Area Served
8.1.2 Deltanoid Pharmaceuticals Inc Product Introduction, Application and Specification
8.1.3 Deltanoid Pharmaceuticals Inc Secondary Hyperparathyroidism Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.1.4 Main Business and Markets Served
8.2 EA Pharma Co Ltd
8.2.1 EA Pharma Co Ltd Secondary Hyperparathyroidism Drug Production Sites and Area Served
8.2.2 EA Pharma Co Ltd Product Introduction, Application and Specification
8.2.3 EA Pharma Co Ltd Secondary Hyperparathyroidism Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.2.4 Main Business and Markets Served
8.3 Lupin Ltd
8.3.1 Lupin Ltd Secondary Hyperparathyroidism Drug Production Sites and Area Served
8.3.2 Lupin Ltd Product Introduction, Application and Specification
8.3.3 Lupin Ltd Secondary Hyperparathyroidism Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.3.4 Main Business and Markets Served
8.4 Mitsubishi Tanabe Pharma Corp
8.4.1 Mitsubishi Tanabe Pharma Corp Secondary Hyperparathyroidism Drug Production Sites and Area Served
8.4.2 Mitsubishi Tanabe Pharma Corp Product Introduction, Application and Specification
8.4.3 Mitsubishi Tanabe Pharma Corp Secondary Hyperparathyroidism Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.4.4 Main Business and Markets Served
8.5 OPKO Health Inc
8.5.1 OPKO Health Inc Secondary Hyperparathyroidism Drug Production Sites and Area Served
8.5.2 OPKO Health Inc Product Introduction, Application and Specification
8.5.3 OPKO Health Inc Secondary Hyperparathyroidism Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.5.4 Main Business and Markets Served
8.6 Shire Plc
8.6.1 Shire Plc Secondary Hyperparathyroidism Drug Production Sites and Area Served
8.6.2 Shire Plc Product Introduction, Application and Specification
8.6.3 Shire Plc Secondary Hyperparathyroidism Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.6.4 Main Business and Markets Served

9 Development Trend of Analysis of Secondary Hyperparathyroidism Drug Market
9.1 Global Secondary Hyperparathyroidism Drug Market Trend Analysis
9.1.1 Global Secondary Hyperparathyroidism Drug Market Size (Volume and Value) Forecast 2019-2025
9.2 Secondary Hyperparathyroidism Drug Regional Market Trend
9.2.1 North America Secondary Hyperparathyroidism Drug Forecast 2019-2025
9.2.2 Europe Secondary Hyperparathyroidism Drug Forecast 2019-2025
9.2.3 China Secondary Hyperparathyroidism Drug Forecast 2019-2025
9.2.4 Japan Secondary Hyperparathyroidism Drug Forecast 2019-2025
9.2.5 Southeast Asia Secondary Hyperparathyroidism Drug Forecast 2019-2025
9.2.6 India Secondary Hyperparathyroidism Drug Forecast 2019-2025
9.3 Secondary Hyperparathyroidism Drug Market Trend (Product Type)
9.4 Secondary Hyperparathyroidism Drug Market Trend (Application)

10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.3 Secondary Hyperparathyroidism Drug Customers

11 Market Dynamics
11.1 Market Trends
11.2 Opportunities
11.3 Market Drivers
11.4 Challenges
11.5 Influence Factors

12 Conclusion
13 Appendix
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Author List
13.4 Disclaimer

List of Tables and Figures
Figure Picture of Secondary Hyperparathyroidism Drug
Table Global Secondary Hyperparathyroidism Drug Production (K Pcs) Growth Rate Comparison by Types (2014-2025)
Figure Global Secondary Hyperparathyroidism Drug Production Market Share by Types in 2018
Figure Evocalcet Product Picture
Figure LNP-1892 Product Picture
Figure AJT-240 Product Picture
Figure Cinacalcet Hydrochloride Product Picture
Figure CTA-091 Product Picture
Figure Others Product Picture
Table Global Secondary Hyperparathyroidism Drug Consumption (K Pcs) Comparison by Applications (2014-2025)
Figure Global Secondary Hyperparathyroidism Drug Consumption Market Share by Applications in 2018
Figure Hospital
Figure Clinic
Figure Others
Figure Global Secondary Hyperparathyroidism Drug Revenue (Million USD) (2014-2025)
Figure Global Secondary Hyperparathyroidism Drug Production (K Pcs) (2014-2025)
Figure North America Secondary Hyperparathyroidism Drug Market Size (Million USD) (2014-2025)
Figure Europe Secondary Hyperparathyroidism Drug Market Size (Million USD) (2014-2025)
Figure China Secondary Hyperparathyroidism Drug Market Size (Million USD) (2014-2025)
Figure Japan Secondary Hyperparathyroidism Drug Market Size (Million USD) (2014-2025)
Figure Southeast Asia Secondary Hyperparathyroidism Drug Market Size (Million USD) (2014-2025)
Figure India Secondary Hyperparathyroidism Drug Market Size (Million USD) (2014-2025)
Table Secondary Hyperparathyroidism Drug Raw Material and Suppliers
Table Manufacturing Cost Structure Analysis of Secondary Hyperparathyroidism Drug in 2018
Figure Manufacturing Process Analysis of Secondary Hyperparathyroidism Drug
Figure Industry Chain Structure of Secondary Hyperparathyroidism Drug
Table Capacity and Commercial Production Date of Key Manufacturers
Table Global Secondary Hyperparathyroidism Drug Manufacturing Plants Distribution
Table Secondary Hyperparathyroidism Drug Major Manufacturers Technology Source and Market Position
Table Recent Development and Expansion Plans in Future
Table Secondary Hyperparathyroidism Drug Capacity (K Pcs) of Major Manufacturers (2014-2019)
Table Secondary Hyperparathyroidism Drug Production (K Pcs) of Major Manufacturers (2014-2019)
Table Secondary Hyperparathyroidism Drug Production Market Share of Major Manufacturers (2014-2019)
Figure Secondary Hyperparathyroidism Drug Production Share by Manufacturers in 2018
Table Secondary Hyperparathyroidism Drug Revenue (Million US$) of Major Manufacturers (2014-2019)
Table Secondary Hyperparathyroidism Drug Revenue Market Share of Major Manufacturers (2014-2019)
Figure Secondary Hyperparathyroidism Drug Revenue Share by Manufacturers in 2018
Table Secondary Hyperparathyroidism Drug Average Price (USD/Pcs) of Major Manufacturers (2014-2019)
Table Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table Global Secondary Hyperparathyroidism Drug Production by Regions 2014-2019 (K Pcs)
Table Global Secondary Hyperparathyroidism Drug Production Market Share by Regions 2014-2019
Figure Global Secondary Hyperparathyroidism Drug Production Market Share by Regions in 2018
Table Global Secondary Hyperparathyroidism Drug Revenue by Regions 2014-2019 (Million USD)
Table Global Secondary Hyperparathyroidism Drug Revenue Market Share by Regions 2014-2019
Figure Global Secondary Hyperparathyroidism Drug Revenue Market Share by Regions in 2018
Table Global Secondary Hyperparathyroidism Drug Consumption by Regions 2014-2019 (K Pcs)
Table Global Secondary Hyperparathyroidism Drug Consumption Market Share by Regions 2014-2019
Figure North America Secondary Hyperparathyroidism Drug Production Growth Rate 2014-2019 (K Pcs)
Figure North America Secondary Hyperparathyroidism Drug Revenue Growth Rate 2014-2019 (Million USD)
Table North America Secondary Hyperparathyroidism Drug Production, Consumption Import and Export (K Pcs)
Figure Europe Secondary Hyperparathyroidism Drug Production Growth Rate 2014-2019 (K Pcs)
Figure Europe Secondary Hyperparathyroidism Drug Revenue Growth Rate 2014-2019 (Million USD)
Table Europe Secondary Hyperparathyroidism Drug Production, Consumption Import and Export (K Pcs)
Figure China Secondary Hyperparathyroidism Drug Production Growth Rate 2014-2019 (K Pcs)
Figure China Secondary Hyperparathyroidism Drug Revenue Growth Rate 2014-2019 (Million USD)
Table China Secondary Hyperparathyroidism Drug Production, Consumption Import and Export (K Pcs)
Figure Japan Secondary Hyperparathyroidism Drug Production Growth Rate 2014-2019 (K Pcs)
Figure Japan Secondary Hyperparathyroidism Drug Revenue Growth Rate 2014-2019 (Million USD)
Table Japan Secondary Hyperparathyroidism Drug Production, Consumption Import and Export (K Pcs)
Figure Southeast Asia Secondary Hyperparathyroidism Drug Production Growth Rate 2014-2019 (K Pcs)
Figure Southeast Asia Secondary Hyperparathyroidism Drug Revenue Growth Rate 2014-2019 (Million USD)
Table Southeast Asia Secondary Hyperparathyroidism Drug Production, Consumption Import and Export (K Pcs)
Figure India Secondary Hyperparathyroidism Drug Production Growth Rate 2014-2019 (K Pcs)
Figure India Secondary Hyperparathyroidism Drug Revenue Growth Rate 2014-2019 (Million USD)
Table India Secondary Hyperparathyroidism Drug Production, Consumption Import and Export (K Pcs)
Figure Global Consumption Secondary Hyperparathyroidism Drug Market Share by Application (2014-2019)
Figure Global Value (Consumption) Secondary Hyperparathyroidism Drug Market Share by Application (2014-2019)
Table Deltanoid Pharmaceuticals Inc Secondary Hyperparathyroidism Drug Production Sites and Area Served
Table Deltanoid Pharmaceuticals Inc Secondary Hyperparathyroidism Drug Product Introduction, Application and Specification
Table Deltanoid Pharmaceuticals Inc Secondary Hyperparathyroidism Drug Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table Deltanoid Pharmaceuticals Inc Secondary Hyperparathyroidism Drug Production Growth Rate (2014-2019)
Table Deltanoid Pharmaceuticals Inc Secondary Hyperparathyroidism Drug Production Market Share (2014-2019)
Figure Deltanoid Pharmaceuticals Inc Secondary Hyperparathyroidism Drug Revenue Market Share (2014-2019)
Table Deltanoid Pharmaceuticals Inc Secondary Hyperparathyroidism Drug Main Business and Markets Served
Table EA Pharma Co Ltd Secondary Hyperparathyroidism Drug Production Sites and Area Served
Table EA Pharma Co Ltd Secondary Hyperparathyroidism Drug Product Introduction, Application and Specification
Table EA Pharma Co Ltd Secondary Hyperparathyroidism Drug Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table EA Pharma Co Ltd Secondary Hyperparathyroidism Drug Production Growth Rate (2014-2019)
Table EA Pharma Co Ltd Secondary Hyperparathyroidism Drug Production Market Share (2014-2019)
Figure EA Pharma Co Ltd Secondary Hyperparathyroidism Drug Revenue Market Share (2014-2019)
Table EA Pharma Co Ltd Secondary Hyperparathyroidism Drug Main Business and Markets Served
Table Lupin Ltd Secondary Hyperparathyroidism Drug Production Sites and Area Served
Table Lupin Ltd Secondary Hyperparathyroidism Drug Product Introduction, Application and Specification
Table Lupin Ltd Secondary Hyperparathyroidism Drug Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table Lupin Ltd Secondary Hyperparathyroidism Drug Production Growth Rate (2014-2019)
Table Lupin Ltd Secondary Hyperparathyroidism Drug Production Market Share (2014-2019)
Figure Lupin Ltd Secondary Hyperparathyroidism Drug Revenue Market Share (2014-2019)
Table Lupin Ltd Secondary Hyperparathyroidism Drug Main Business and Markets Served
Table Mitsubishi Tanabe Pharma Corp Secondary Hyperparathyroidism Drug Production Sites and Area Served
Table Mitsubishi Tanabe Pharma Corp Secondary Hyperparathyroidism Drug Product Introduction, Application and Specification
Table Mitsubishi Tanabe Pharma Corp Secondary Hyperparathyroidism Drug Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table Mitsubishi Tanabe Pharma Corp Secondary Hyperparathyroidism Drug Production Growth Rate (2014-2019)
Table Mitsubishi Tanabe Pharma Corp Secondary Hyperparathyroidism Drug Production Market Share (2014-2019)
Figure Mitsubishi Tanabe Pharma Corp Secondary Hyperparathyroidism Drug Revenue Market Share (2014-2019)
Table Mitsubishi Tanabe Pharma Corp Secondary Hyperparathyroidism Drug Main Business and Markets Served
Table OPKO Health Inc Secondary Hyperparathyroidism Drug Production Sites and Area Served
Table OPKO Health Inc Secondary Hyperparathyroidism Drug Product Introduction, Application and Specification
Table OPKO Health Inc Secondary Hyperparathyroidism Drug Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table OPKO Health Inc Secondary Hyperparathyroidism Drug Production Growth Rate (2014-2019)
Table OPKO Health Inc Secondary Hyperparathyroidism Drug Production Market Share (2014-2019)
Figure OPKO Health Inc Secondary Hyperparathyroidism Drug Revenue Market Share (2014-2019)
Table OPKO Health Inc Secondary Hyperparathyroidism Drug Main Business and Markets Served
Table Shire Plc Secondary Hyperparathyroidism Drug Production Sites and Area Served
Table Shire Plc Secondary Hyperparathyroidism Drug Product Introduction, Application and Specification
Table Shire Plc Secondary Hyperparathyroidism Drug Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table Shire Plc Secondary Hyperparathyroidism Drug Production Growth Rate (2014-2019)
Table Shire Plc Secondary Hyperparathyroidism Drug Production Market Share (2014-2019)
Figure Shire Plc Secondary Hyperparathyroidism Drug Revenue Market Share (2014-2019)
Table Shire Plc Secondary Hyperparathyroidism Drug Main Business and Markets Served
Figure Global Secondary Hyperparathyroidism Drug Production (K Pcs) Growth Rate Forecast 2019-2025
Figure Global Secondary Hyperparathyroidism Drug Revenue (Million USD) Growth Rate Forecast 2019-2025
Figure Global Secondary Hyperparathyroidism Drug Sales Price (USD/Pcs) Forecast 2019-2025
Figure North America Secondary Hyperparathyroidism Drug Production Growth Rate Forecast 2019-2025 (K Pcs)
Figure North America Secondary Hyperparathyroidism Drug Revenue Growth Rate Forecast 2019-2025 (Million USD)
Figure Europe Secondary Hyperparathyroidism Drug Production Growth Rate Forecast 2019-2025 (K Pcs)
Figure Europe Secondary Hyperparathyroidism Drug Revenue Growth Rate Forecast 2019-2025 (Million USD)
Figure China Secondary Hyperparathyroidism Drug Production Growth Rate Forecast 2019-2025 (K Pcs)
Figure China Secondary Hyperparathyroidism Drug Revenue Growth Rate Forecast 2019-2025 (Million USD)
Figure Japan Secondary Hyperparathyroidism Drug Production Growth Rate Forecast 2019-2025 (K Pcs)
Figure Japan Secondary Hyperparathyroidism Drug Revenue Growth Rate Forecast 2019-2025 (Million USD)
Figure Southeast Asia Secondary Hyperparathyroidism Drug Production Growth Rate Forecast 2019-2025 (K Pcs)
Figure Southeast Asia Secondary Hyperparathyroidism Drug Revenue Growth Rate Forecast 2019-2025 (Million USD)
Figure India Secondary Hyperparathyroidism Drug Production Growth Rate Forecast 2019-2025 (K Pcs)
Figure India Secondary Hyperparathyroidism Drug Revenue Growth Rate Forecast 2019-2025 (Million USD)
Table Global Production (K Pcs) of Secondary Hyperparathyroidism Drug by Type (2019-2025)
Table Global Consumption (K Pcs) of Secondary Hyperparathyroidism Drug by Application (2019-2025)
Table Secondary Hyperparathyroidism Drug Distributors List
Table Secondary Hyperparathyroidism Drug Customers List
Table Market Key Trends
Table Key Opportunities
Table Market Key Drivers
Table Key Challenges
Table Key Influence Factors
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources


【掲載企業】

Deltanoid Pharmaceuticals Inc、EA Pharma Co Ltd、Lupin Ltd、Mitsubishi Tanabe Pharma Corp、OPKO Health Inc、Shire Plc、

★調査レポート[世界の二次性副甲状腺機能亢進薬市場 2019年] (コード：DATA909X14807)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の二次性副甲状腺機能亢進薬市場 2019年]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界の膿痂疹薬市場 2019年
    DATA909X09571 / QYResearch / 2019年11月20日 / ※本調査レポートは、膿痂疹薬の世界市場概要、製造コスト分析、開発・製造工場分析、主要メーカー分析、地域別分析情報、市場規模予測データ、マーケティングチャネル、流通業者リスト、顧客リストなどが含まれています。種類別には、FMX-102、LTX-109、ムピロシン、オゼノキサシン、その他に、用途別には、クリニック、病院、その他にセグメント区分し、膿痂疹薬の世界市場を分析しました。 ・エグゼクティブ・サマリー ・膿痂疹薬の世界市場概要 ・膿痂疹薬の製造コスト構成分析 ・膿痂疹薬の開発・製造工場分析 ・主要メーカーの主な指標（生産能力、売上、価格分析） ・膿痂疹薬の地域別分析（生産、売上、主要メーカー、輸出・輸入） （北米、ヨーロッパ、中国、日本国内、東南アジア、インド） ・膿痂疹薬のセグメント分析（種類別） （FMX-102、LTX-109、ムピロシン、オゼノキサシン、その他）...The global Impetigo Drug market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Impetigo Drug volume and value at global level, regional level and company level. From a global perspective, this report represents overall Impetigo Drug market size by analyzing historical data and future prospect. Regionally, this report categorizes the production, apparent consumption, export and import of Impetigo Drug in North America, Europe, China, Japan, Southeast Asia and India. For each manufacturer covered, this report analyzes their Impetigo Drug manufacturing...
  • 世界のパーキンソン病薬市場 2019年
    DATA909X12634 / QYResearch / 2019年11月20日 / ※本調査レポートは、パーキンソン病薬の世界市場概要、製造コスト分析、開発・製造工場分析、主要メーカー分析、地域別分析情報、市場規模予測データ、マーケティングチャネル、流通業者リスト、顧客リストなどが含まれています。種類別には、シネメット-CR、トラスター、マドパル、COMT阻害剤、その他に、用途別には、40歳未満、40-65歳、65歳以上にセグメント区分し、パーキンソン病薬の世界市場を分析しました。 ・エグゼクティブ・サマリー ・パーキンソン病薬の世界市場概要 ・パーキンソン病薬の製造コスト構成分析 ・パーキンソン病薬の開発・製造工場分析 ・主要メーカーの主な指標（生産能力、売上、価格分析） ・パーキンソン病薬の地域別分析（生産、売上、主要メーカー、輸出・輸入） （北米、ヨーロッパ、中国、日本国内、東南アジア、インド） ・パーキンソン病薬のセグメント分析（種類別） （シネメット-CR、トラスター、マドパル、COMT阻害剤、その他）...The global Parkinson's Disease Drug market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Parkinson's Disease Drug volume and value at global level, regional level and company level. From a global perspective, this report represents overall Parkinson's Disease Drug market size by analyzing historical data and future prospect. Regionally, this report categorizes the production, apparent consumption, export and import of Parkinson's Disease Drug in North America, Europe, China, Japan, Southeast Asia and India. For each manufacturer covered, this report analyzes...
  • 世界のクローン病薬市場 2019年
    DATA909X06111 / QYResearch / 2019年11月15日 / ※本調査レポートは、クローン病薬の世界市場概要、製造コスト分析、開発・製造工場分析、主要メーカー分析、地域別分析情報、市場規模予測データ、マーケティングチャネル、流通業者リスト、顧客リストなどが含まれています。種類別には、アミノサリチル酸（5-ASA）、コルチコステロイド、免疫調節薬、抗生物質に、用途別には、寛解の達成（症状の欠如）、寛解の維持（再燃の予防）、小児クローン病にセグメント区分し、クローン病薬の世界市場を分析しました。 ・エグゼクティブ・サマリー ・クローン病薬の世界市場概要 ・クローン病薬の製造コスト構成分析 ・クローン病薬の開発・製造工場分析 ・主要メーカーの主な指標（生産能力、売上、価格分析） ・クローン病薬の地域別分析（生産、売上、主要メーカー、輸出・輸入） （北米、ヨーロッパ、中国、日本国内、東南アジア、インド） ・クローン病薬のセグメント分析（種類別） （アミノサリチル酸（5-ASA）、コルチコステロイド、免疫調節薬、抗生物質）...The global Crohn’s Disease Drug market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Crohn’s Disease Drug volume and value at global level, regional level and company level. From a global perspective, this report represents overall Crohn’s Disease Drug market size by analyzing historical data and future prospect. Regionally, this report categorizes the production, apparent consumption, export and import of Crohn’s Disease Drug in North America, Europe, China, Japan, Southeast Asia and India. For each manufacturer covered, this report analyzes...
  • 世界の視神経症薬市場 2019年
    DATA909X12314 / QYResearch / 2019年11月20日 / ※本調査レポートは、視神経症薬の世界市場概要、製造コスト分析、開発・製造工場分析、主要メーカー分析、地域別分析情報、市場規模予測データ、マーケティングチャネル、流通業者リスト、顧客リストなどが含まれています。種類別には、BA-240、IWP-953、LM-22A4、その他に、用途別には、クリニック、病院、在宅ケアにセグメント区分し、視神経症薬の世界市場を分析しました。 ・エグゼクティブ・サマリー ・視神経症薬の世界市場概要 ・視神経症薬の製造コスト構成分析 ・視神経症薬の開発・製造工場分析 ・主要メーカーの主な指標（生産能力、売上、価格分析） ・視神経症薬の地域別分析（生産、売上、主要メーカー、輸出・輸入） （北米、ヨーロッパ、中国、日本国内、東南アジア、インド） ・視神経症薬のセグメント分析（種類別） （BA-240、IWP-953、LM-22A4、その他）...The global Optic Neuropathy Drug market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Optic Neuropathy Drug volume and value at global level, regional level and company level. From a global perspective, this report represents overall Optic Neuropathy Drug market size by analyzing historical data and future prospect. Regionally, this report categorizes the production, apparent consumption, export and import of Optic Neuropathy Drug in North America, Europe, China, Japan, Southeast Asia and India. For each manufacturer covered, this report analyzes...
  • 世界の腎盂腎炎炎薬市場 2019年
    DATA909X13967 / QYResearch / 2019年11月20日 / ※本調査レポートは、腎盂腎炎炎薬の世界市場概要、製造コスト分析、開発・製造工場分析、主要メーカー分析、地域別分析情報、市場規模予測データ、マーケティングチャネル、流通業者リスト、顧客リストなどが含まれています。種類別には、フィナフロキサシン、ホスホマイシントロメタミン、ナクバクタム、硫酸プラゾマイシン、その他に、用途別には、病院、診療所、その他にセグメント区分し、腎盂腎炎炎薬の世界市場を分析しました。 ・エグゼクティブ・サマリー ・腎盂腎炎炎薬の世界市場概要 ・腎盂腎炎炎薬の製造コスト構成分析 ・腎盂腎炎炎薬の開発・製造工場分析 ・主要メーカーの主な指標（生産能力、売上、価格分析） ・腎盂腎炎炎薬の地域別分析（生産、売上、主要メーカー、輸出・輸入） （北米、ヨーロッパ、中国、日本国内、東南アジア、インド） ・腎盂腎炎炎薬のセグメント分析（種類別） （フィナフロキサシン、ホスホマイシントロメタミン、ナクバクタム、硫酸プラゾマイシン、その他）...The global Pyelonephritis Drug market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Pyelonephritis Drug volume and value at global level, regional level and company level. From a global perspective, this report represents overall Pyelonephritis Drug market size by analyzing historical data and future prospect. Regionally, this report categorizes the production, apparent consumption, export and import of Pyelonephritis Drug in North America, Europe, China, Japan, Southeast Asia and India. For each manufacturer covered, this report analyzes their Pyelonephritis Drug manufacturing...
  • 世界の動脈血栓症薬市場 2019年
    DATA909X03729 / QYResearch / 2019年11月15日 / ※本調査レポートは、動脈血栓症薬の世界市場概要、製造コスト分析、開発・製造工場分析、主要メーカー分析、地域別分析情報、市場規模予測データ、マーケティングチャネル、流通業者リスト、顧客リストなどが含まれています。種類別には、AS-1468240、ASP-6537、BAY-1213790、BMS-65445、その他に、用途別には、クリニック、病院、その他にセグメント区分し、動脈血栓症薬の世界市場を分析しました。 ・エグゼクティブ・サマリー ・動脈血栓症薬の世界市場概要 ・動脈血栓症薬の製造コスト構成分析 ・動脈血栓症薬の開発・製造工場分析 ・主要メーカーの主な指標（生産能力、売上、価格分析） ・動脈血栓症薬の地域別分析（生産、売上、主要メーカー、輸出・輸入） （北米、ヨーロッパ、中国、日本国内、東南アジア、インド） ・動脈血栓症薬のセグメント分析（種類別） （AS-1468240、ASP-6537、BAY-1213790、BMS-65445、その他）...The global Arterial Thrombosis Drug market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Arterial Thrombosis Drug volume and value at global level, regional level and company level. From a global perspective, this report represents overall Arterial Thrombosis Drug market size by analyzing historical data and future prospect. Regionally, this report categorizes the production, apparent consumption, export and import of Arterial Thrombosis Drug in North America, Europe, China, Japan, Southeast Asia and India. For each manufacturer covered, this report analyzes...
  • 世界の平滑筋肉腫薬市場 2019年
    DATA909X10490 / QYResearch / 2019年11月20日 / ※本調査レポートは、平滑筋肉腫薬の世界市場概要、製造コスト分析、開発・製造工場分析、主要メーカー分析、地域別分析情報、市場規模予測データ、マーケティングチャネル、流通業者リスト、顧客リストなどが含まれています。種類別には、AL-3818、BGB-290、C-21、その他に、用途別には、クリニック、病院、その他にセグメント区分し、平滑筋肉腫薬の世界市場を分析しました。 ・エグゼクティブ・サマリー ・平滑筋肉腫薬の世界市場概要 ・平滑筋肉腫薬の製造コスト構成分析 ・平滑筋肉腫薬の開発・製造工場分析 ・主要メーカーの主な指標（生産能力、売上、価格分析） ・平滑筋肉腫薬の地域別分析（生産、売上、主要メーカー、輸出・輸入） （北米、ヨーロッパ、中国、日本国内、東南アジア、インド） ・平滑筋肉腫薬のセグメント分析（種類別） （AL-3818、BGB-290、C-21、その他）...The global Leiomyosarcoma Drug market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Leiomyosarcoma Drug volume and value at global level, regional level and company level. From a global perspective, this report represents overall Leiomyosarcoma Drug market size by analyzing historical data and future prospect. Regionally, this report categorizes the production, apparent consumption, export and import of Leiomyosarcoma Drug in North America, Europe, China, Japan, Southeast Asia and India. For each manufacturer covered, this report analyzes their Leiomyosarcoma Drug manufacturing...
  • 世界の進行性多巣性白質脳症治療薬市場 2019年
    DATA909X13789 / QYResearch / 2019年11月20日 / ※本調査レポートは、進行性多巣性白質脳症治療薬の世界市場概要、製造コスト分析、開発・製造工場分析、主要メーカー分析、地域別分析情報、市場規模予測データ、マーケティングチャネル、流通業者リスト、顧客リストなどが含まれています。種類別には、EBT-103、IKT-01427、メシル酸イマチニブ、NI-307、その他に、用途別には、病院、診療所、研究センターにセグメント区分し、進行性多巣性白質脳症治療薬の世界市場を分析しました。 ・エグゼクティブ・サマリー ・進行性多巣性白質脳症治療薬の世界市場概要 ・進行性多巣性白質脳症治療薬の製造コスト構成分析 ・進行性多巣性白質脳症治療薬の開発・製造工場分析 ・主要メーカーの主な指標（生産能力、売上、価格分析） ・進行性多巣性白質脳症治療薬の地域別分析（生産、売上、主要メーカー、輸出・輸入） （北米、ヨーロッパ、中国、日本国内、東南アジア、インド） ・進行性多巣性白質脳症治療薬のセグメント分析（種類別） （EBT-103、IKT-01427、メシル酸イマチニブ、NI-307、その他）...The global Progressive Multifocal Leukoencephalopathy Drug market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Progressive Multifocal Leukoencephalopathy Drug volume and value at global level, regional level and company level. From a global perspective, this report represents overall Progressive Multifocal Leukoencephalopathy Drug market size by analyzing historical data and future prospect. Regionally, this report categorizes the production, apparent consumption, export and import of Progressive Multifocal Leukoencephalopathy Drug in North America, Europe, China, Japan, Southeast Asia and India. For each manufacturer...

    • ◆H&Iグローバルリサーチのお客様（例）◆